CH Peptides
Every formulation is curated with lab-grade ingredients, and we're syncing up the freshest data from our inventory so you see accurate availability as soon as the app loads.
Loading live inventory
Syncing 24 research sprays
Verifying lab supplies
Supabase + Stripe ready
Orders placed before 2 P.M. PST Monday through Friday are shipped out same day!
Looks like you haven't added any products to your cart yet.
Loading...
ARA-290, also known as pyroglutamate helix B surface peptide (pHBSP), is a derivative of erythropoietin's helix B domain. Research codes or alternative naming conventions have primarily referred to it as ARA-290 or pHBSP without additional designations.
The peptide sequence for ARA-290 is Ac-SLTTLLRALGAWGEHPGK-F-NH2, comprising 11 amino acids with specific N-terminal acetylation and C-terminal amidation. This sequence mimics the helix B region of erythropoietin, which is pivotal for its biological activity.
ARA-290 targets the innate repair receptor (IRR), a heteromeric receptor complex formed by the erythropoietin receptor (EPOR) and β-common receptor (βcR). It functions as an agonist, promoting anti-inflammatory and tissue protective pathways. Key signaling pathways include PI3K/Akt and MAPK/ERK, resulting in cytoprotective and regenerative effects. The EC50 or IC50 values specific to receptor interactions have yet to be extensively characterized in literature.
ARA-290 is soluble in sterile water at concentrations of 1 mg/mL. It is recommended to reconstitute the peptide in an appropriate solvent prior to experimental protocols. Lyophilized ARA-290 is stable for up to 24 months at -20°C, whereas reconstituted solutions should be stored at -80°C and used within a month to ensure biological activity.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.
ARA-290, also known as pyroglutamate helix B surface peptide (pHBSP), is a derivative of erythropoietin's helix B domain. Research codes or alternative naming conventions have primarily referred to it as ARA-290 or pHBSP without additional designations.
The peptide sequence for ARA-290 is Ac-SLTTLLRALGAWGEHPGK-F-NH2, comprising 11 amino acids with specific N-terminal acetylation and C-terminal amidation. This sequence mimics the helix B region of erythropoietin, which is pivotal for its biological activity.
ARA-290 targets the innate repair receptor (IRR), a heteromeric receptor complex formed by the erythropoietin receptor (EPOR) and β-common receptor (βcR). It functions as an agonist, promoting anti-inflammatory and tissue protective pathways. Key signaling pathways include PI3K/Akt and MAPK/ERK, resulting in cytoprotective and regenerative effects. The EC50 or IC50 values specific to receptor interactions have yet to be extensively characterized in literature.
ARA-290 is soluble in sterile water at concentrations of 1 mg/mL. It is recommended to reconstitute the peptide in an appropriate solvent prior to experimental protocols. Lyophilized ARA-290 is stable for up to 24 months at -20°C, whereas reconstituted solutions should be stored at -80°C and used within a month to ensure biological activity.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.
Chorionic Gonadotropin; commonly abbreviated as HCG. It is a glycoprotein hormone composed of alpha and beta subunits, predominantly characterized in human pregnancy. No specific research codes or development codes are associated with the basic glycoprotein.
HCG is a heterodimeric protein composed of two non-covalently linked subunits: the alpha subunit (92 amino acids) shared with other hormones like LH, FSH, and TSH, and the beta subunit (145 amino acids) which is unique to HCG. The beta subunit contains distinct segments: H-Trp-Met-Ser-Glu-His-Ile-Thr-Arg-Tyr-Leu-... and features specific disulfide bridges essential for activity and stability.
HCG acts as an agonist to the luteinizing hormone/chorionic gonadotropin receptor (LHCG receptor). Binding of HCG to its receptor activates pathways such as the cAMP/PKA signaling cascade, promoting steroidogenesis. EC50 values are variable based on assay and cellular system but are indicative of potent agonist activity.
HCG is soluble in sterile water at concentrations of 1mg/mL for research applications. Upon reconstitution, the solution must be stored at 2-8°C and is stable for up to 24 hours. Lyophilized HCG remains stable at -20°C until reconstitution.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.
Retatrutide is referred to by its research code LY3502970. As of current knowledge, alternative naming conventions in the literature have not been extensively established.
Retatrutide is a peptide compound consisting of 39 amino acids. The exact amino acid sequence is: H-Thr-Lys-Asp-Glu-Leu-Gln-Ala-Ile-Arg-Trp-Leu-Lys-His-Glu-Arg-Asp-His-Gly-Ile-Lys-Lys-Glu-Cys-Leu-Glu-Glu-Val-Leu-Asp-Ser-Leu-Ala-Arg-Ala-Glu-Glu-Arg-OH. Specific modifications include N-terminal acetylation and C-terminal amidation to enhance its activity and stability. It is structurally designed to interact with multiple peptide receptors.
Retatrutide acts as an agonist at multiple receptors, including the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR), exhibiting multifaceted activity. Its mechanism enhances several intracellular signaling pathways, notably the cAMP/PKA and PI3K/Akt cascades. It demonstrates a unique binding profile, combining activities that influence metabolic pathways associated with glucose and lipid handling.
Retatrutide is notably soluble in sterile water at a concentration of 1mg/mL. For research applications, it is recommended to reconstitute the lyophilized form in an appropriate buffer and store it at -20°C to maintain stability. Once reconstituted, it remains stable for up to 3 weeks if stored under proper conditions.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.
Retatrutide is referred to by its research code LY3502970. As of current knowledge, alternative naming conventions in the literature have not been extensively established.
Retatrutide is a peptide compound consisting of 39 amino acids. The exact amino acid sequence is: H-Thr-Lys-Asp-Glu-Leu-Gln-Ala-Ile-Arg-Trp-Leu-Lys-His-Glu-Arg-Asp-His-Gly-Ile-Lys-Lys-Glu-Cys-Leu-Glu-Glu-Val-Leu-Asp-Ser-Leu-Ala-Arg-Ala-Glu-Glu-Arg-OH. Specific modifications include N-terminal acetylation and C-terminal amidation to enhance its activity and stability. It is structurally designed to interact with multiple peptide receptors.
Retatrutide acts as an agonist at multiple receptors, including the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR), exhibiting multifaceted activity. Its mechanism enhances several intracellular signaling pathways, notably the cAMP/PKA and PI3K/Akt cascades. It demonstrates a unique binding profile, combining activities that influence metabolic pathways associated with glucose and lipid handling.
Retatrutide is notably soluble in sterile water at a concentration of 1mg/mL. For research applications, it is recommended to reconstitute the lyophilized form in an appropriate buffer and store it at -20°C to maintain stability. Once reconstituted, it remains stable for up to 3 weeks if stored under proper conditions.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.